Failed Bioquivalence Studies Should Accompany ANDAs, FDA's Conner Says
Executive Summary
FDA is considering issuing a guidance with instructions for ANDA sponsors on submitting failed bioequivalence studies.
You may also be interested in...
Failed bioequivalence submissions
FDA proposes amending its ANDA in vivo bioequivalence regulations to require submission of data "from all BE studies the applicant conducts on a drug product formulation submitted for approval," instead of only those studies meeting the necessary BE criteria. The amended regs will require "all additional passing and nonpassing BE studies conducted" to be submitted "in either a complete or summary report," HHS' Unified Agenda for 2002 says. The advance notice of proposed rulemaking is due out in February. FDA is concerned that submissions often do not include failed BE studies (1"The Pink Sheet" Oct. 23, 2000, p. 25)...
Failed bioequivalence submissions
FDA proposes amending its ANDA in vivo bioequivalence regulations to require submission of data "from all BE studies the applicant conducts on a drug product formulation submitted for approval," instead of only those studies meeting the necessary BE criteria. The amended regs will require "all additional passing and nonpassing BE studies conducted" to be submitted "in either a complete or summary report," HHS' Unified Agenda for 2002 says. The advance notice of proposed rulemaking is due out in February. FDA is concerned that submissions often do not include failed BE studies (1"The Pink Sheet" Oct. 23, 2000, p. 25)...
SangStat To Sell Transplant Pharmacy To Chain Drug Store By Q1 2001
SangStat expects to sell its specialty mail-order service, The Transplant Pharmacy, to a chain drug store by the end of the first quarter 2001.